Compare Abeona Therapeutics Inc (ABEO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Eli Lilly And Co — how do they compare? Abeona Therapeutics Inc trades at $5.6 (market cap $319.66M), while Eli Lilly And Co trades at $1,146.89 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 3222.2× Abeona Therapeutics Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abeona Therapeutics Inc for 22 Days and Eli Lilly And Co for 92 Days on average.
| ABEO | LLY | |
|---|---|---|
Market Cap | $319.66M | $1.03T |
Volume | 3,459,993 | 1,879,873 |
Sector | Health | Health |
52-Week High | $7.46 | $1.28K |
52-Week Low | $4.17 | $714.59 |
Typical Hold Time | 22 Days | 92 Days |
Enterprise Value | $192.70M | $1.07T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $5.60, up 4.28% today, but faces a bearish technical outlook with strong sell signals from moving averages. The company reported a net loss of $63M in 2026 with a negative net margin of -246.43%, though quarterly EPS has shown some beats. Recent news highlights ongoing legal investigations and operational challenges, but also expansion of treatment centers and positive Medicare payment status for ZEVASKYN.
The investment case balances deep value from low EV/EBITDA of 3.82 and strong analyst buy ratings (66.7% consensus) against severe profitability issues and legal overhangs. Upside hinges on successful commercialization of ZEVASKYN, while downside risks include persistent losses and litigation outcomes.
Eli Lilly (LLY) trades at $1,142.12, up 0.34% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Analyst consensus is strongly bullish, with a $1,340 price target, supported by positive news on its obesity drug pipeline and market share gains.
LLY's outlook remains positive due to dominant positioning in weight-loss drugs and a promising pipeline, but risks include clinical setbacks and high valuation multiples. The stock offers growth potential, though investors should weigh execution risks against strong financial performance and analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
